The Business of Biosimilars: The Key Challenges of Pharma Forecasting

Stephen Lamb and Art Cook


When biosimilars launch, the dynamics that will play out in a given therapy area or geography are highly uncertain. Given that biosimilars represent an entirely new product category—one with just a handful of early examples to date—the challenges to the forecaster are unique and formidable. The challenges apply equally to those tasked with forecasting biosimilar uptake or originator erosion.

In this white paper, Stephen Lamb and Art Cook weigh in on these challenges, assess the dynamics at play in the market at various points in the forecast funnel, and share their thoughts on the future of biosimilar forecasting.

About the Experts

Stephen Lamb

Stephen Lamb is a strategy insights and planning manager in ZS’s San Francisco office. He focuses on forecasting, market research and modeling engagements at both emerging and large biopharmaceutical companies. Stephen’s experience spans early pipeline, pre-launch and inline issues including indication prioritization, opportunity assessments and a range of other forecasting-related topics.

Art Cook is a principal in ZS’s San Francisco office. He has led several practice area teams within ZS, including forecasting and portfolio strategy. He currently leads ZS’s biosimilars center of excellence, which supports ZS teams in engagements related to biosimilar products. Art has an extensive range of international forecasting and portfolio optimization experience, and he is the author of the 2015 book, Forecasting for the Pharmaceutical Industry.